Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.325    0.075 (6.00%)
Bid:
1.25
Ask:
1.40
Spread: 0.15 (12.00%)
Market Cap: £21.27m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

18 Jul 2019 07:00

RNS Number : 9066F
Genedrive PLC
18 July 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

 

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Ian Gilham

 

 

2.

Reason for the notification

a.

Position/status

Non-Executive Chairman

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

19p

51,250

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

N/A

 

e.

Date of the transaction

2019-07-17; UTC time

f.

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO

 

Matthew Fowler: CFO

 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel

 

Oliver Jackson

 

 

Stanford Capital Partners Limited

 

+44 (0)20 3815 8880

 

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

 

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAEXXFSSNEAF
Date   Source Headline
25th Jan 202111:05 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
18th Jan 202112:29 pmRNSHolding(s) in Company
18th Jan 20217:00 amRNSNotice of Results
30th Dec 202012:50 pmRNSResult of AGM
23rd Dec 202011:39 amRNSHolding(s) in Company
21st Dec 20202:48 pmRNSResponse to new COVID strain
17th Dec 20209:12 amRNSHolding(s) in Company
16th Dec 20209:05 amRNSSecond Price Monitoring Extn
16th Dec 20209:00 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSNotification of intent to distribute in the USA
11th Dec 20207:00 amRNSConversion of Remaining Loan Notes
7th Dec 20207:00 amRNSAdditional Listing
3rd Dec 20207:00 amRNSAIHL hospital study completion
30th Nov 20207:00 amRNSBlock listing Interim Review
26th Nov 20204:41 pmRNSSecond Price Monitoring Extn
26th Nov 20204:35 pmRNSPrice Monitoring Extension
20th Nov 20207:00 amRNSHigh clinical accuracy in India study
17th Nov 20207:00 amRNSFinal Results
10th Nov 202011:05 amRNSSecond Price Monitoring Extn
10th Nov 202011:00 amRNSPrice Monitoring Extension
2nd Nov 20204:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20204:35 pmRNSPrice Monitoring Extension
29th Oct 20207:00 amRNSNotice of Results
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:36 pmRNSPrice Monitoring Extension
22nd Oct 20207:00 amRNSPoint-of-Care solution to detect SARS-CoV-2 virus
19th Oct 202012:44 pmRNSHolding(s) in Company
12th Oct 202011:18 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSHolding(s) in Company
6th Oct 20207:00 amRNSHolding(s) in Company
1st Oct 20206:09 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSSouth African approval
28th Sep 20207:00 amRNSPartial Conversion of Loan Notes
25th Sep 20207:00 amRNSVerification with Beckman Coulter Life Sciences
21st Sep 20209:40 amRNSHolding(s) in Company
18th Sep 20202:06 pmRNSSecond Price Monitoring Extn
18th Sep 20202:01 pmRNSPrice Monitoring Extension
17th Sep 20209:27 amRNSHolding(s) in Company
16th Sep 20203:15 pmRNSHolding(s) in Company
16th Sep 20209:00 amRNSHolding(s) in Company
15th Sep 20201:12 pmRNSHolding(s) in Company
14th Sep 20204:40 pmRNSSecond Price Monitoring Extn
14th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:00 amRNSHolding(s) in Company
4th Aug 20202:05 pmRNSSecond Price Monitoring Extn
4th Aug 20202:00 pmRNSPrice Monitoring Extension
4th Aug 20207:00 amRNSCollaboration to automate COVID-19 PCR testing
23rd Jul 202011:06 amRNSSecond Price Monitoring Extn
23rd Jul 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.